Research visual

Health Research

Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer

Powell AC, Mirhadi AJ, Loy BA, Happe LE, Long JW, Kren EM, et al. (2017) Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer. PLoS ONE 12(7): e0181319.

https://doi.org/10.1371/journal.pone.0181319

Incidence of non-melanoma skin cancer in the Medicare population

Rogers H, Puente J, Happe LE, Loy B, Beveridge M. Incidence of non-melanoma skin cancer in the Medicare population. Poster presentation at: National Comprehensive Cancer Network Annual Conference. March 23-25, 2017. Orlando, Florida.

http://apps.humana.com/marketing/documents.asp?file=3107923

PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan

Ems D, Kennedy K, Gregory F, et al. PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan. Poster presentation at: Academy of Managed Care Pharmacy Nexus 2016 Conference. October 4, 2016; National Harbor, MD.

http://apps.humana.com/marketing/documents.asp?file=3058757

Presentation at diagnosis and intensity of interventions in people with lung cancer

Powell AC, Mirhadi AJ, Loy BA, Long JW, Kren EM, Gupta AK. Presentation at diagnosis and intensity of interventions in people with lung cancer. J Clin Oncol. 2016;34(suppl; abstr e20052).

Presentation at diagnosis and intensity of interventions in people with lung cancer. | 2016 ASCO Annual Meeting | Abstra…

Refill patterns with oral oncolytic medications

Dye JT, Murty S, Nsiah I, Kennedy K, Whisman T, Worley K. Refill patterns with oral oncolytic medications. J Clin Oncol. 2016;34(suppl; abstr e18216).

Refill patterns with oral oncolytic medications. | 2016 ASCO Annual Meeting | Abstracts | Meeting Library

Effectiveness of colorectal cancer screening messaging among individuals non-compliant with guidelines

Jhaveri M,  Cambon J, Cordier T, Haugh G.  Effectiveness of colorectal cancer screening messaging among individuals non-compliant with guidelines.  J Natl Compr Canc Netw. 2016;14(5.5):e1-e30.

http://apps.humana.com/marketing/documents.asp?file=2857348

Patterns of care in patients with metastatic renal cell carcinoma among a US payer population

Miller LA, Stemkowski S, Saverno K, Lane D, Tao Z, Hackshaw M, Loy B. Patterns of care in patients with metastatic renal cell carcinoma among a US payer population. J Manag Care Spec Pharm, 2016;22(3):219-226

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.3.219

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan

MacLean EA, Louder AM, Saverno KR, Smith G, Mardekian J, Bruins C, Ward M, Sweetman RW, Pasquale M. Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan. American Journal of Managed Care 2016; 22(2): e60-e67.

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large U.S. health plan. | 2014 AS…

Effect of new drug therapies on current metastatic melanoma treatment patterns

Kennedy K, Murty S, Dye J, Whisman T, Worley K. Effect of new drug therapies on current metastatic melanoma treatment patterns. J Natl Compr Canc Netw. 2016;14(5.5):e1-e30.

http://apps.humana.com/marketing/documents.asp?file=2852434

Do case rates affect physicians’ clinical practice in radiation oncology

Loy BA, Shkedy, CI, Powell AC, Happe LE, Royalty JA, Miao MT, Smith GL, Long JW, Gupta AK.  Do case rates affect physicians’ clinical practice in radiation oncology? PLoS One. 2016;11(2):e0149449.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752271/pdf/pone.0149449.pdf

Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2452333

Cincinnati's adoption of a web-based portal to promote reportable evidence-based care

Loy B, Gallagher J, Peterson B, Forston S, Sturgill M. Cincinnati's adoption of a web-based portal to promote reportable evidence-based care. Poster presentation at: American Society of Clinical Oncology Quality Care Symposium. October 17-18, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2501603

Longitudinal evaluation of a colorectal cancer screenings measurement model

Loy B, Brooks WT, Yang M, Happe LE, Van Gilder T. Longitudinal evaluation of a colorectal cancer screenings measurement model. J Natl Compr Canc Netw. 2015;13:624.

https://apps.humana.com/marketing/documents.asp?file=2584010

Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma

Racsa P, Worley K, Whisman T. Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma. J Natl Compr Canc Netw. 2015;13:625-26.

https://apps.humana.com/marketing/documents.asp?file=2584023

Do case rates affect physicians' clinical practice in radiation oncology?

Loy B, Royalty J, Shkedy C, Tankersley M, Altonen B. Do case rates affect physicians' clinical practice in radiation oncology? Podium presentation at: American Society of Clinical Oncology (ASCO) Quality Care Symposium. October, 2014; Boston, MA.

Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here?

Hayes MS, Ward MA, Slabaugh SL, Xu Y. Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here? Am Drug Health Benefits. 2014;7(5):264-270.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163778/

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Ward MA, Fang G, Richards KL, et al. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin. 2015;31(2):289-97.

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors…

Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. J Health Econ Outcomes Res. 2015;2(2):181-91.

Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients

Racsa PN, Whisman TR, Worley K. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin. 2015;31(10):1933-40.

http://www.ncbi.nlm.nih.gov/pubmed/26368665

Descriptive analysis of patients initiating regorafenib therapy in a large managed care population

Slabaugh L, Louder A, Michels SL, et al. Descriptive analysis of patients initiating regorafenib therapy in a large managed care population. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2573987

Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer

Powell AC, Mirhadi AJ, Loy BA, Happe LE, Long JW, Kren EM, et al. (2017) Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer. PLoS ONE 12(7): e0181319.

https://doi.org/10.1371/journal.pone.0181319

Incidence of non-melanoma skin cancer in the Medicare population

Rogers H, Puente J, Happe LE, Loy B, Beveridge M. Incidence of non-melanoma skin cancer in the Medicare population. Poster presentation at: National Comprehensive Cancer Network Annual Conference. March 23-25, 2017. Orlando, Florida.

http://apps.humana.com/marketing/documents.asp?file=3107923

PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan

Ems D, Kennedy K, Gregory F, et al. PD-1 inhibitor prescribing patterns and utilization trends in a large national health plan. Poster presentation at: Academy of Managed Care Pharmacy Nexus 2016 Conference. October 4, 2016; National Harbor, MD.

http://apps.humana.com/marketing/documents.asp?file=3058757

Presentation at diagnosis and intensity of interventions in people with lung cancer

Powell AC, Mirhadi AJ, Loy BA, Long JW, Kren EM, Gupta AK. Presentation at diagnosis and intensity of interventions in people with lung cancer. J Clin Oncol. 2016;34(suppl; abstr e20052).

Presentation at diagnosis and intensity of interventions in people with lung cancer. | 2016 ASCO Annual Meeting | Abstra…

Refill patterns with oral oncolytic medications

Dye JT, Murty S, Nsiah I, Kennedy K, Whisman T, Worley K. Refill patterns with oral oncolytic medications. J Clin Oncol. 2016;34(suppl; abstr e18216).

Refill patterns with oral oncolytic medications. | 2016 ASCO Annual Meeting | Abstracts | Meeting Library

Effectiveness of colorectal cancer screening messaging among individuals non-compliant with guidelines

Jhaveri M,  Cambon J, Cordier T, Haugh G.  Effectiveness of colorectal cancer screening messaging among individuals non-compliant with guidelines.  J Natl Compr Canc Netw. 2016;14(5.5):e1-e30.

http://apps.humana.com/marketing/documents.asp?file=2857348

Patterns of care in patients with metastatic renal cell carcinoma among a US payer population

Miller LA, Stemkowski S, Saverno K, Lane D, Tao Z, Hackshaw M, Loy B. Patterns of care in patients with metastatic renal cell carcinoma among a US payer population. J Manag Care Spec Pharm, 2016;22(3):219-226

http://www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.3.219

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan

MacLean EA, Louder AM, Saverno KR, Smith G, Mardekian J, Bruins C, Ward M, Sweetman RW, Pasquale M. Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large US health plan. American Journal of Managed Care 2016; 22(2): e60-e67.

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large U.S. health plan. | 2014 AS…

Effect of new drug therapies on current metastatic melanoma treatment patterns

Kennedy K, Murty S, Dye J, Whisman T, Worley K. Effect of new drug therapies on current metastatic melanoma treatment patterns. J Natl Compr Canc Netw. 2016;14(5.5):e1-e30.

http://apps.humana.com/marketing/documents.asp?file=2852434

Do case rates affect physicians’ clinical practice in radiation oncology

Loy BA, Shkedy, CI, Powell AC, Happe LE, Royalty JA, Miao MT, Smith GL, Long JW, Gupta AK.  Do case rates affect physicians’ clinical practice in radiation oncology? PLoS One. 2016;11(2):e0149449.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752271/pdf/pone.0149449.pdf

Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Comparative outcomes of patients newly initiating first-generation vs. second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Poster presentation at: Academy of Managed Care Pharmacy Nexus. October 7-10, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2452333

Cincinnati's adoption of a web-based portal to promote reportable evidence-based care

Loy B, Gallagher J, Peterson B, Forston S, Sturgill M. Cincinnati's adoption of a web-based portal to promote reportable evidence-based care. Poster presentation at: American Society of Clinical Oncology Quality Care Symposium. October 17-18, 2014; Boston, MA.

http://apps.humana.com/marketing/documents.asp?file=2501603

Longitudinal evaluation of a colorectal cancer screenings measurement model

Loy B, Brooks WT, Yang M, Happe LE, Van Gilder T. Longitudinal evaluation of a colorectal cancer screenings measurement model. J Natl Compr Canc Netw. 2015;13:624.

https://apps.humana.com/marketing/documents.asp?file=2584010

Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma

Racsa P, Worley K, Whisman T. Comparing costs and health outcomes in initial therapy with sunitinib versus pazopanib for renal cell carcinoma. J Natl Compr Canc Netw. 2015;13:625-26.

https://apps.humana.com/marketing/documents.asp?file=2584023

Do case rates affect physicians' clinical practice in radiation oncology?

Loy B, Royalty J, Shkedy C, Tankersley M, Altonen B. Do case rates affect physicians' clinical practice in radiation oncology? Podium presentation at: American Society of Clinical Oncology (ASCO) Quality Care Symposium. October, 2014; Boston, MA.

Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here?

Hayes MS, Ward MA, Slabaugh SL, Xu Y. Lessons from the leucovorin shortage between 2009 and 2012 in a Medicare Advantage population: where do we go from here? Am Drug Health Benefits. 2014;7(5):264-270.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163778/

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Ward MA, Fang G, Richards KL, et al. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin. 2015;31(2):289-97.

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors…

Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Ward MA, Fang G, Richards K, et al. Treatment interruption and regimen change in first-generation versus second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. J Health Econ Outcomes Res. 2015;2(2):181-91.

Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients

Racsa PN, Whisman TR, Worley K. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin. 2015;31(10):1933-40.

http://www.ncbi.nlm.nih.gov/pubmed/26368665

Descriptive analysis of patients initiating regorafenib therapy in a large managed care population

Slabaugh L, Louder A, Michels SL, et al. Descriptive analysis of patients initiating regorafenib therapy in a large managed care population. Poster presentation at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting. May 31-June 4, 2014; Montreal, QC, Canada.

http://apps.humana.com/marketing/documents.asp?file=2573987